The real estate sector has pinned high hopes on the Union Budget FY 2025-26 documents and is keeping its fingers crossed regarding their expectations from the government's most important financial ...
Under the terms of the alliance, Ascendis will carry out the early development of TransCon product candidates, funded by Novo Nordisk, with the pharma group taking over once they reach the ...
Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...
About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform ... safety or efficacy results in Ascendis’ development programs or on-market products ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback